Infusystem Holdings, INC (INFU) — SEC Filings

Q: What are the key financial highlights for Infusystem Holdings, INC?

Key financial highlights for Infusystem Holdings, INC are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Infusystem Holdings, INC?

Key executives at Infusystem Holdings, INC are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Infusystem Holdings, INC stock?

Risk factors for Infusystem Holdings, INC (INFU) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Infusystem Holdings, INC?

Forward-looking statements and predictions from Infusystem Holdings, INC are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Infusystem Holdings, INC. Recent 8-K filing on Dec 10, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Infusystem Holdings, INC on SEC EDGAR

Overview

Infusystem Holdings, INC (INFU) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 4, 2025: InfuSystem Holdings, Inc. filed an 8-K on November 4, 2025, reporting on its Results of Operations and Financial Condition. The filing details the company's financial status and operational performance as of the reporting date. InfuSystem Holdings, Inc. is incorporated in Delaware and headquartered

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 4 bullish, 1 bearish, 45 neutral. The dominant filing sentiment for Infusystem Holdings, INC is neutral.

Filing Type Overview

Infusystem Holdings, INC (INFU) has filed 36 8-K, 5 10-Q, 1 DEF 14A, 2 10-K, 3 SC 13D/A, 1 DEFA14A, 1 SC 13G/A, 1 SC 13G with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

8-K Filing — 8-K · Dec 10, 2025
8-K Filing — 8-K · Nov 13, 2025
8-K Filing — 8-K · Nov 10, 2025
InfuSystem Holdings, Inc. Files 8-K on Financials — 8-K · Nov 4, 2025 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on November 4, 2025, reporting on its Results of Operations and Financial Condition. The filing details the company's fin
InfuSystem Holdings Files 8-K for Regulation FD Disclosure — 8-K · Oct 28, 2025 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on October 28, 2025, to report a Regulation FD Disclosure. The filing does not contain specific details about the nature
InfuSystem Holdings Files 8-K for Regulation FD Disclosure — 8-K · Oct 6, 2025 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on October 6, 2025, to report a Regulation FD Disclosure. The filing does not contain specific details about the nature o
InfuSystem Holdings Files 8-K for Regulation FD Disclosure — 8-K · Sep 25, 2025 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on September 25, 2025, to report a Regulation FD Disclosure. The filing does not contain specific details about the natur
InfuSystem Q2 Net Income Jumps 78% on Strong Revenue Growth — 10-Q · Aug 5, 2025 Risk: low
InfuSystem Holdings, Inc. reported a robust financial performance for the second quarter ended June 30, 2025, and the six months ended June 30, 2025. For the th
InfuSystem Holdings Files 8-K for Regulation FD Disclosure — 8-K · Jul 29, 2025 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on July 29, 2025, to report a Regulation FD Disclosure. The filing does not contain specific details about the nature of
InfuSystem Holdings Enters New Credit Agreement — 8-K · Jul 17, 2025 Risk: low
On July 15, 2025, InfuSystem Holdings, Inc. entered into a material definitive agreement, specifically a credit agreement, which creates a direct financial obli
InfuSystem Holdings Inc. Files 8-K for Corporate Changes — 8-K · Jun 3, 2025 Risk: medium
InfuSystem Holdings, Inc. announced on May 29, 2025, a significant change in its corporate structure and governance. The company filed an 8-K detailing amendmen
InfuSystem Holdings Announces Director Changes and Shareholder Votes — 8-K · May 20, 2025 Risk: medium
InfuSystem Holdings, Inc. announced on May 15, 2025, a series of significant corporate actions. These include the departure of a director, the election of new d
InfuSystem Holdings Files 8-K for Regulation FD Disclosure — 8-K · May 9, 2025 Risk: medium
InfuSystem Holdings, Inc. filed an 8-K on May 9, 2025, to report a Regulation FD Disclosure. The filing does not contain specific details about the nature of th
InfuSystem Holdings Q1 2025 10-Q Filed — 10-Q · May 8, 2025 Risk: medium
InfuSystem Holdings, Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's financial performance and operational upda
InfuSystem Holdings Files 8-K for Regulation FD Disclosure — 8-K · May 1, 2025 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on May 1, 2025, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or material
InfuSystem Holdings DEF 14A: Executive Compensation Details — DEF 14A · Apr 10, 2025 Risk: low
InfuSystem Holdings, Inc. filed its DEF 14A on April 10, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing include
InfuSystem Holdings Announces Director and Officer Changes — 8-K · Apr 1, 2025 Risk: medium
InfuSystem Holdings, Inc. announced on March 31, 2025, changes related to its directors and officers. The filing details the departure of certain officers and d
InfuSystem Holdings Files 2024 10-K — 10-K · Mar 11, 2025 Risk: low
InfuSystem Holdings, Inc. filed its 2024 10-K on March 11, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as HAPC, Inc
InfuSystem Holdings Files 8-K on Financials — 8-K · Mar 4, 2025 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on March 4, 2025, to report on its results of operations and financial condition. The filing provides updated information
InfuSystem Holdings Files 8-K for Regulation FD Disclosure — 8-K · Feb 25, 2025 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on February 25, 2025, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or mat
Sansone Advisors Ups Stake in InfuSystem Holdings — SC 13D/A · Dec 9, 2024 Risk: medium
On December 9, 2024, Sansone Advisors, LLC, through Christopher Sansone, filed an amendment (Amendment No. 3) to its Schedule 13D regarding InfuSystem Holdings,
Shuda Amends InfuSystem Holdings Stake — SC 13D/A · Dec 6, 2024 Risk: medium
Scott A. Shuda, through Meridian OHC Partners, LP, has filed an amendment (No. 4) to their Schedule 13D for InfuSystem Holdings, Inc. The filing, dated December
InfuSystem Holdings Files 8-K for Regulation FD Disclosure — 8-K · Dec 4, 2024 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on December 4, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or mate
InfuSystem Holdings Files 8-K for Regulation FD Disclosure — 8-K · Nov 22, 2024 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on November 22, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or tra
InfuSystem Holdings Appoints New Directors, Updates Executive Contracts — 8-K · Nov 18, 2024 Risk: medium
InfuSystem Holdings, Inc. announced on November 12, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two ne
InfuSystem Holdings Q3 2024 Revenue Hits $45.3M — 10-Q · Nov 8, 2024 Risk: medium
InfuSystem Holdings, Inc. reported its Q3 2024 results, with total revenue for the nine months ending September 30, 2024, reaching $45.3 million. The company's
InfuSystem Holdings Reports Financial Condition — 8-K · Nov 7, 2024 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on November 7, 2024, to report on its results of operations and financial condition. The filing provides information abou
InfuSystem Holdings Files 8-K for Regulation FD Disclosure — 8-K · Oct 31, 2024 Risk: medium
InfuSystem Holdings, Inc. filed an 8-K on October 31, 2024, to report a Regulation FD Disclosure. The filing does not contain specific details about the nature
InfuSystem Holdings Files 8-K for Regulation FD Disclosure — 8-K · Sep 27, 2024 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on September 27, 2024, to report a Regulation FD Disclosure. The filing does not contain specific details about the natur
Sansone Advisors Amends InfuSystem Holdings Stake — SC 13D/A · Sep 24, 2024 Risk: medium
On September 24, 2024, Sansone Advisors, LLC, through Christopher Sansone, filed an amendment to its Schedule 13D, reporting a change in beneficial ownership of
InfuSystem Holdings Files 8-K for Regulation FD Disclosure — 8-K · Sep 12, 2024 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on September 12, 2024, to report a Regulation FD Disclosure. The filing does not contain specific details about the natur
InfuSystem Holdings Files 8-K for Regulation FD Disclosure — 8-K · Sep 11, 2024 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on September 11, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or ma
InfuSystem to be Acquired for $1 Billion — 8-K · Sep 4, 2024 Risk: medium
InfuSystem Holdings, Inc. announced on September 4, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of Patient Square Capit
InfuSystem Holdings Q2 2024 10-Q Filing — 10-Q · Aug 9, 2024 Risk: medium
InfuSystem Holdings, Inc. reported its Q2 2024 results for the period ending June 30, 2024. The company's financial statements reflect its operations and financ
InfuSystem Holdings, Inc. Files 8-K on Financials — 8-K · Aug 8, 2024 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on August 8, 2024, to report on its results of operations and financial condition. The filing does not contain specific f
InfuSystem Holdings Files 8-K for Regulation FD Disclosure — 8-K · Aug 6, 2024 Risk: medium
InfuSystem Holdings, Inc. filed an 8-K on August 6, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or detail
InfuSystem Holdings Files 8-K for Regulation FD Disclosure — 8-K · Aug 2, 2024 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on August 2, 2024, to report a Regulation FD Disclosure. The filing does not contain specific details about the nature of
InfuSystem to be Acquired for $1.1 Billion — 8-K · Jun 12, 2024 Risk: low
InfuSystem Holdings, Inc. announced on June 12, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of Patient Square Capital.
InfuSystem Holdings Files 8-K for Regulation FD Disclosure — 8-K · Jun 4, 2024 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on June 4, 2024, to report a Regulation FD Disclosure. The filing does not contain specific details about the nature of t
InfuSystem Holdings to be Acquired by Patient Square Capital — 8-K · May 20, 2024 Risk: medium
InfuSystem Holdings, Inc. announced on May 16, 2024, that it entered into a definitive agreement to be acquired by an affiliate of Patient Square Capital. The t
InfuSystem Holdings Sets Annual Meeting Date — 8-K · May 17, 2024 Risk: low
InfuSystem Holdings, Inc. announced on May 16, 2024, that it will hold its 2024 Annual Meeting of Stockholders on June 27, 2024. The meeting will include a vote
InfuSystem Holdings, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: low
InfuSystem Holdings, Inc (INFU) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. InfuSystem Holdings, Inc. filed a 10-Q report for the period ending
InfuSystem to be Acquired for $1 Billion — 8-K · May 2, 2024 Risk: low
InfuSystem Holdings, Inc. announced on May 2, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of Patient Square Capital. Th
InfuSystem Holdings DEFA14A Filing — DEFA14A · Apr 23, 2024 Risk: low
InfuSystem Holdings, Inc. filed a Definitive Additional Materials (DEFA14A) on April 23, 2024. This filing relates to the company's proxy statement and indicate
InfuSystem Holdings, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Apr 10, 2024 Risk:
InfuSystem Holdings, Inc (INFU) filed a Annual Report (10-K) with the SEC on April 10, 2024. InfuSystem Holdings, Inc. filed its 2023 Form 10-K on April 10, 202
InfuSystem Faces NYSE Delisting Warning — 8-K · Apr 3, 2024 Risk: high
InfuSystem Holdings, Inc. announced on April 2, 2024, that it received a notice from the NYSE American indicating that the company is not in compliance with cer
InfuSystem Holdings Files 8-K for Operations Update — 8-K · Mar 14, 2024 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on March 14, 2024, to report on its results of operations and financial condition. The filing does not contain specific f
InfuSystem Holdings Files 8-K for Regulation FD Disclosure — 8-K · Mar 8, 2024 Risk: low
InfuSystem Holdings, Inc. filed an 8-K on March 8, 2024, to report a Regulation FD Disclosure. The filing does not contain specific details about the nature of
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G Filing — SC 13G · Feb 13, 2024

Risk Profile

Risk Assessment: Of INFU's 44 recent filings, 1 were flagged as high-risk, 15 as medium-risk, and 28 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Infusystem Holdings, INC's most recent 10-Q filing (Aug 5, 2025):

Revenue: $30.5M
Net Income: $3.2M
EPS: $0.14
Debt-to-Equity: N/A
Cash Position: $13.7M
Operating Margin: N/A
Total Assets: $131.6M
Total Debt: $10.1M

Key Executives

Christopher Sansone
Scott A. Shuda
Michael J. O'Malley
David A. Smith
Steven R. Johnson
Jonathan P. Rose

Industry Context

InfuSystem operates in the medical device rental and services sector, primarily serving oncology and pain management. The industry is characterized by a need for specialized equipment, reliable service, and adherence to healthcare regulations. Key trends include the increasing demand for home healthcare solutions and the outsourcing of medical equipment management by healthcare providers.

Top Tags

regulation-fd (14) · disclosure (14) · 8-K (6) · financial-condition (5) · 10-Q (4) · acquisition (4) · merger (4) · Regulation FD (3) · Disclosure (3) · corporate-governance (3)

Key Numbers

Q2 2025 Total Revenue: $30.5M — 12.9% increase from Q2 2024
Q2 2025 Net Income: $3.2M — 77.8% increase from Q2 2024
Q2 2025 Diluted EPS: $0.14 — Increased from $0.08 in Q2 2024
H1 2025 Total Revenue: $59.8M — 10.7% increase from H1 2024
H1 2025 Net Income: $5.9M — 68.6% increase from H1 2024
Q2 2025 Revenue Growth: 12.9% — Year-over-year increase
Q2 2025 Net Income Growth: 77.8% — Year-over-year increase
Reporting Period: Q1 2025 — First quarter of fiscal year 2025
Period End Date: 2025-03-31 — The end date for the financial data presented
Prior Year Period End: 2024-03-31 — For comparison with the current period
Fiscal Year: 2024 — Period covered by the executive compensation details in the filing.
Prior Fiscal Year: 2023 — Comparative period
Shares Owned: 1,500,000 — Represents beneficial ownership by Sansone Advisors, LLC
Ownership Stake: 5.1% — Percentage of InfuSystem Holdings' outstanding common stock
Revenue (YTD): $45.3M — Represents the total revenue for the nine months ending September 30, 2024.

Related Companies

ISYS · IHS

Frequently Asked Questions

What are the latest SEC filings for Infusystem Holdings, INC (INFU)?

Infusystem Holdings, INC has 50 recent SEC filings from Feb 2024 to Dec 2025, including 36 8-K, 5 10-Q, 3 SC 13D/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of INFU filings?

Across 50 filings, the sentiment breakdown is: 4 bullish, 1 bearish, 45 neutral. The dominant sentiment is neutral.

Where can I find Infusystem Holdings, INC SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Infusystem Holdings, INC (INFU) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Infusystem Holdings, INC?

Key financial highlights from Infusystem Holdings, INC's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for INFU?

The investment thesis for INFU includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Infusystem Holdings, INC?

Key executives identified across Infusystem Holdings, INC's filings include Christopher Sansone, Scott A. Shuda, Michael J. O'Malley, David A. Smith, Steven R. Johnson and 1 others.

What are the main risk factors for Infusystem Holdings, INC stock?

Of INFU's 44 assessed filings, 1 were flagged high-risk, 15 medium-risk, and 28 low-risk.

What are recent predictions and forward guidance from Infusystem Holdings, INC?

Forward guidance and predictions for Infusystem Holdings, INC are extracted from SEC filings as they are enriched.